# Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

> **NCT00061672** · PHASE2 · COMPLETED · sponsor: **Abbott** · enrollment: 67 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Hodgkin's Lymphoma

## Interventions

- **DRUG:** ABT-510 - Thrombospondin-1 Mimetic

## Key facts

- **NCT ID:** NCT00061672
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2007-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00061672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00061672, "Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00061672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*